Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer
- PMID: 11843249
- DOI: 10.1023/a:1013569329846
Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer
Abstract
Purpose: SIR-Spheres are radioactive yttrium90 microspheres (SIR-Spheres, Sirtex Medical Limited, Australia) used to selectively target high levels of ionising radiation to tumors within the liver. This trial was designed to measure any increased patient benefit by adding a single administration of SIR-Spheres to a regimen of regional hepatic artery chemotherapy (HAC) administered as a 12 day infusion of floxuridine and repeated at monthly intervals, vs. the same chemotherapy alone.
Patients and methods: A phase III randomised clinical trial entering 74 patients was undertaken on patients with bi-lobar non-resectable liver metastases from primary adenocarcinoma of the large bowel. Patient benefit criteria assessed in the trial were tumor response, time to disease progression in the liver, overall survival, quality of life, and treatment related toxicity. Tumor response was measured by serial changes in both cross-sectional tumor areas and total tumor volumes, provided any response lasted not less than three months as well as changes in serum carcino-embryonic antigen (CEA).
Results: The partial and complete response rate (PR + CR) was significantly greater for patients receiving SIR-Spheres when measured by tumor areas (44%) vs. 17.6%, P = 0.01) tumor volumes (50% vs. 24%, P = 0.03) and CEA (72% vs. 47%, P = 0.004). The median time to disease progression in the liver was significantly longer for patients receiving SIR-Spheres in comparison to patients receiving HAC alone when measured by either tumor areas (9.7 vs. 15.9 months, P = 0.001), tumor volumes (7.6 vs. 12.0 months, P = 0.04) or CEA (5.7 vs. 6.7 months, P = 0.06). The one, two, three and five-year survival for patients receiving SIR-Spheres was 72%, 39%, 17% and 3.5%, compared to 68%, 29%, 6.5% and 0% for HAC alone. Cox regression analysis suggests an improvement in survival for patients treated with SIR-Spheres who survive more than 15 months (P = 0.06). There was no increase in grade 3-4 treatment related toxicity and no loss of quality of life for patients receiving SIR-Spheres in comparison to patients receiving HAC alone.
Conclusion: The combination of a single injection of SIR-Spheres plus HAC is substantially more effective in increasing tumor responses and progression free survival than the same regimen of HAC alone.
Similar articles
-
Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.J Surg Oncol. 2004 Nov 1;88(2):78-85. doi: 10.1002/jso.20141. J Surg Oncol. 2004. PMID: 15499601 Clinical Trial.
-
Selective internal radiation therapy for liver metastases from colorectal cancer.Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD007045. doi: 10.1002/14651858.CD007045.pub2. Cochrane Database Syst Rev. 2009. PMID: 19821394 Free PMC article. Review.
-
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.J Clin Oncol. 2007 Mar 20;25(9):1099-106. doi: 10.1200/JCO.2006.08.7916. J Clin Oncol. 2007. PMID: 17369573 Clinical Trial.
-
Regression of liver metastases following treatment with yttrium-90 microspheres.Aust N Z J Surg. 1992 Feb;62(2):105-10. doi: 10.1111/j.1445-2197.1992.tb00006.x. Aust N Z J Surg. 1992. PMID: 1586298
-
Selective internal radiation therapy for liver metastases from colorectal cancer.Cancer Treat Rev. 2016 Nov;50:148-154. doi: 10.1016/j.ctrv.2016.09.007. Epub 2016 Sep 10. Cancer Treat Rev. 2016. PMID: 27690234 Review.
Cited by
-
Current status of yttrium-90 microspheres radioembolization in primary and metastatic liver cancer.J Interv Med. 2023 Sep 19;6(4):153-159. doi: 10.1016/j.jimed.2023.09.001. eCollection 2023 Nov. J Interv Med. 2023. PMID: 38312126 Free PMC article.
-
Economic evaluations of radioembolization with yttrium-90 microspheres in liver metastases of colorectal cancer: a systematic review.BMC Gastroenterol. 2023 May 24;23(1):181. doi: 10.1186/s12876-023-02793-5. BMC Gastroenterol. 2023. PMID: 37226091 Free PMC article.
-
Intra-Arterial Delivery of Radiopharmaceuticals in Oncology: Current Trends and the Future of Alpha-Particle Therapeutics.Pharmaceutics. 2023 Apr 4;15(4):1138. doi: 10.3390/pharmaceutics15041138. Pharmaceutics. 2023. PMID: 37111624 Free PMC article. Review.
-
Temporary Reversal of Hepatoenteric Collaterals during 90Y Radioembolization Planning and Administration.Curr Oncol. 2022 Dec 6;29(12):9582-9592. doi: 10.3390/curroncol29120753. Curr Oncol. 2022. PMID: 36547167 Free PMC article.
-
A Primer on Radiopharmaceutical Therapy.Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):48-59. doi: 10.1016/j.ijrobp.2022.08.010. Epub 2022 Aug 13. Int J Radiat Oncol Biol Phys. 2023. PMID: 35970373 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials